Nonetheless, we are confident of the robustness of the N_LyST tests as detailed in the previous publication, describing the high frequency of BRAF mutants and MLH1 methylation within the MSI of the UK CRC samples, with near perfect agreement with some standard methods [29]. This evidence concerns the gene BRAF and colorectal carcinoma.